Capillary leak syndrome in a patient with cancer-associated anti-transcriptional intermediary factor 1γ dermatomyositis treated with rituximab.

Autor: Palermo BL; Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy. biancalucia.palermo01@universitadipavia.it., Bottazzi F; Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy., Dourado E; Rheumatology Department, Centro Hospitalar Universitário Lisboa Norte (CHULN), Centro Académico de Medicina de Lisboa (CAML), Lisbon, ERN ReCONNET Full Member, and Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, CAML, Lisbon, Portugal., Codullo V; Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy, ERN ReCONNET Full Member., Civardi L; Anaesthesia and Intensive Care, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy., Zanframundo G; Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy., Cavagna L; Rheumatology Division, IRCCS Policlinico S. Matteo Foundation, Pavia, and University of Pavia, ERN ReCONNET Full Member, and Department of Internal Medicine and Medical Therapeutics, Pavia, Italy.
Jazyk: angličtina
Zdroj: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2022 May; Vol. 40 Suppl 134 (5), pp. 118-120. Date of Electronic Publication: 2022 Feb 22.
DOI: 10.55563/clinexprheumatol/j26b6o
Abstrakt: Capillary leak syndrome (CLS) is a rare condition characterised by increased capillary permeability, with subsequent hypoalbuminemia and hypotension, leading to an increased risk of shock and death. We present the case of a patient with anti-transcriptional intermediary factor 1γ dermatomyositis that developed CLS one week after starting treatment with rituximab and prophylactic co-trimoxazole. The patient was admitted to the Intensive Care Unit (ICU), recovered after treatment with intravenous immunoglobulin, albumin, and Ringer lactate, but died a month after the discharge due to a poorly differentiated hepatocarcinoma diagnosed in the ICU.
Databáze: MEDLINE